Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 12/20 | 0.48 |
| ▸ | HNF4A | P41235 | 3/20 | 0.48 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.43 |
| ▸ | RARA | P10276 | 6/20 | 0.42 |
| ▸ | RARB | P10826 | 6/20 | 0.42 |
| ▸ | RARG | P13631 | 6/20 | 0.42 |
| ▸ | RXRB | P28702 | 5/20 | 0.41 |
| ▸ | RXRG | P48443 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6144637 | 0.93 | RXRA (0.48) | RXRAHNF4ACYP26A1CYP3A4CYP26B1 | |
| SCHEMBL6146627 | 0.93 | RXRA (0.48) | RXRAHNF4ACYP26A1CYP3A4CYP26B1 | |
| SCHEMBL4850568 | 0.88 | RXRA (0.38) | RXRAHNF4ACYP26A1CYP3A4CYP26B1 | |
| SCHEMBL6143581 | 0.88 | CYP26A1 (0.56) | RXRAHNF4ACYP26A1CYP3A4CYP26B1 | |
| SCHEMBL6143658 | 0.84 | CYP26A1 (0.48) | RXRAHNF4ACYP26A1CYP3A4CYP26B1 | |
| SCHEMBL4842332 | 0.84 | CYP26A1 (0.55) | RXRAHNF4ACYP26A1CYP3A4CYP26B1 | |
| SCHEMBL4843603 | 0.84 | RXRA (0.44) | RXRAHNF4ACYP26A1CYP3A4CYP26B1 | |
| SCHEMBL4849371 | 0.83 | RXRA (0.41) | RXRAHNF4ACYP26A1CYP26B1RARA | |
| SCHEMBL14540351 | 0.82 | RXRA (0.36) | RXRAHNF4ARARARARBRARG | |
| SCHEMBL14196320 | 0.82 | RXRA (0.44) | RXRAHNF4ACYP26A1CYP3A4CYP26B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1442032-B1 | HETEROCYCLIC RETINOID COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2007-04-18 | — | — | EP | claimed |
| EP-1442032-A1 | HETEROCYCLIC RETINOID COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-04 | — | — | EP | claimed |
| WO-2003037882-A1 | HETEROCYCLIC RETINOID COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-08 | — | — | WO | claimed |
| US-7354931-B2 | Treating obstructive airway disorders using nontoxic drug | ROCHE PALO ALTO LLC (US) | 2008-04-08 | — | — | US | disclosed |
| US-7354931-B2 | Treating obstructive airway disorders using nontoxic drug | ROCHE PALO ALTO LLC (US) | 2008-04-08 | — | — | US | disclosed |
| US-7354931-B2 | Treating obstructive airway disorders using nontoxic drug | ROCHE PALO ALTO LLC (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1442032-B1 | HETEROCYCLIC RETINOID COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2007-04-18 | — | — | EP | disclosed |
| EP-1442032-B1 | HETEROCYCLIC RETINOID COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2007-04-18 | — | — | EP | disclosed |
| US-20050049238-A1 | Heterocyclic retinoid compounds | KLAUS MICHAEL (DE) | 2005-03-03 | — | — | US | disclosed |
| US-6818652-B2 | THERAPEUTIC TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, CANCER AND DERMATOLOGICAL SKIN DISORDERS | SYNTEX (U.S.A.) LLC | 2004-11-16 | — | — | US | disclosed |
| EP-1442032-A1 | HETEROCYCLIC RETINOID COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-04 | — | — | EP | disclosed |
| US-20030158178-A1 | Heterocyclic retinoid compounds | SYNTEX (U.S.A.) LLC | 2003-08-21 | — | — | US | disclosed |
| WO-2003037882-A1 | HETEROCYCLIC RETINOID COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049238-A1 | Heterocyclic retinoid compounds | RARG, RXRG, RXRA | RXRA 3/4885HNF4A 536/4885CYP26A1 102/4885 |
| US-20030158178-A1 | Heterocyclic retinoid compounds | RARG, RXRG, RXRA | RXRA 3/4885HNF4A 536/4885CYP26A1 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.